A Phase 4 Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan) for 7 Years
Latest Information Update: 20 Oct 2023
At a glance
- Drugs Sapropterin (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Acronyms KOGNITO
- Sponsors BioMarin Pharmaceutical
Most Recent Events
- 21 Apr 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 This trial has been completed in Germany(Global End Date: 26 Jan 2016), according to European Clinical Trials Database record.
- 27 Jul 2020 This trial is completed in UK (Global End Date: 26 Jan 2016), according to European Clinical Trials Database record.